|1.||Yen, Yun: 26 articles (06/2015 - 01/2003)|
|2.||Liu, Xiyong: 16 articles (06/2015 - 10/2006)|
|3.||Szekeres, Thomas: 14 articles (10/2013 - 08/2002)|
|4.||Zhou, Bingsen: 13 articles (06/2015 - 12/2005)|
|5.||Fritzer-Szekeres, Monika: 12 articles (10/2013 - 08/2002)|
|6.||Saiko, Philipp: 11 articles (10/2013 - 01/2004)|
|7.||Grusch, Michael: 10 articles (10/2013 - 08/2002)|
|8.||Krupitza, Georg: 9 articles (10/2013 - 08/2002)|
|9.||Jaeger, Walter: 9 articles (10/2013 - 10/2006)|
|10.||Elford, Howard L: 9 articles (12/2009 - 08/2002)|
11/01/1979 - "These data suggest that combinations of inhibitors of ribonucleotide reductase which specifically inhibit the components may be useful in the treatment of cancer."
01/01/2015 - "As such, this study highlights the potential of a novel cancer therapeutic strategy that exploits the synergy of chaperone and ribonucleotide reductase inhibitors."
10/15/2014 - "EPR studies established the presence of the active form of ribonucleotide reductase, a specific marker for rapidly proliferating tumors, in EMT samples of both control and GS-NO-treated animals. "
04/01/2014 - "A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms."
10/01/2006 - "Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2011 - "The excision repair cross completing group 1 gene product (ERCC1) and the regulatory subunit of ribonucleotide reductase (RRM1) have been reported as being prognostic of outcome and predictive of therapeutic efficacy in patients with non-small cell lung cancer. "
01/01/2015 - "Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status."
01/01/2014 - "We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). "
01/01/2013 - "The roles of excision repair cross-complementing group 1 gene (ERCC1) expression and ribonucleotide reductase subunit M1 gene (RRM1) expression in completely resected non-small cell lung cancer (NSCLC) are still debatable. "
11/01/2012 - "[Ribonucleotide reductase and non-small cell lung cancer]."
12/01/2010 - "To assess whether high ribonucleotide reductase subunit M1 (RRM1) expression in patients with resected, muscle-invasive (T2-4NxM0) urothelial carcinoma (UC) correlated with longer overall survival (OS). "
04/01/2008 - "Fluoropyrimidine based therapy has modest activity in patients with metastatic renal carcinoma and inhibition of ribonucleotide reductase is synergistic in model systems. "
09/01/1998 - "Ribonucleotide reductase levels in colon carcinoma cell lines are much higher than in primary cultures of human hepatocytes. "
09/01/1998 - "Ribonucleotide reductase expression in several colon carcinoma cell lines and in primary cultures of human hepatocytes was determined by Western blot analysis. "
08/01/1998 - "We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2015 - "Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression."
08/01/2004 - "Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer."
12/15/2015 - "The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)."
03/01/2015 - "Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors."
01/01/2014 - "miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells."
|5.||Breast Neoplasms (Breast Cancer)
12/01/2011 - "This study was to investigate whether the expressions of DNA repair genes ERCC1 (excision repair cross complementing 1), RRM1 (ribonucleotide reductase subunit M1) and BRCA1 (breast cancer 1) affected clinical outcome in patients with NSCLC. "
01/01/2012 - "Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer."
03/01/1995 - "Immunohistochemical detection of ribonucleotide reductase in human breast-tumors."
01/01/2015 - "Importantly, the cancer drug target ribonucleotide reductase was shown to be a client of Hsp70 and Hsp90 in both yeast and breast cancer cells. "
11/15/2012 - "The authors of this report investigated the relation of EGFR mutation or ALK rearrangement status and the expression of DNA repair or synthesis genes, including excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthetase (TS), and breast cancer-early onset (BRCA1), as a potential explanation for these observations. "
|4.||Equilibrative Nucleoside Transporter 1
|5.||Small Interfering RNA (siRNA)
|7.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|5.||Pneumonectomy (Lung Volume Reduction)